ClearPoint Neuro

Conventional stereotactic surgery often requires a pre-operative CT scan and a fiducial frame attached to the patient's skull, with surgeons operating without live imaging feedback. ClearPoint uses a skull-mounted aiming device and proprietary software that operates inside the MRI bore, providing the surgeon with real-time, sub-millimeter visualization of probe placement. This closed-bore MRI compatibility eliminates the need to move the patient between scanning and operating rooms, reducing the risk of targeting error and allowing immediate confirmation of drug infusion or electrode position.

It operates in both segments. The functional neurosurgery division sells hardware, disposables, and software licenses to hospitals performing deep-brain stimulation implants and biopsies. The biologics and drug-delivery division contracts with pharmaceutical companies to provide access to the ClearPoint platform for pre-clinical research and human clinical trials. Gene-therapy developers such as uniQure and Voyager Therapeutics rely on the system to infuse their therapeutic payloads directly into target brain regions under live MRI guidance.

Clinical partners are using the platform to deliver gene therapies for neurodegenerative disorders including Parkinson's disease and Huntington's disease. Drug candidates for enzyme-deficiency disorders such as Batten disease and certain lysosomal storage disorders that affect the central nervous system have also been infused via the ClearPoint system in early-phase trials.

The company's unique position as the sole broad-market provider of a closed-bore MRI-guided drug-delivery interface makes it a logical adjacency for larger neuro-modulation or robotic-surgery platforms. Medtronic and Boston Scientific have major deep-brain-stimulation franchises that operate within ClearPoint's procedural footprint, though no acquisition has been publicly discussed. The installed base of over 100 US hospitals and the protocol lock-in with pharma R&D pipelines create substantial switching costs that would be attractive to strategic buyers.

Biotech firms pay service fees for access to the ClearPoint system during pre-clinical animal studies and early-phase human trials. These fees cover device hardware, technical application support from ClearPoint clinical specialists, and data-capture services. As partner drug candidates advance into pivotal human trials, device-related revenue scales with the number of enrolled patients and infusion procedures. The 2023 annual report documented a 30% year-over-year increase in biologics-related service fees.

Joe Burnett serves as President and CEO, having been promoted from the role of Chief Operating Officer. His career includes executive roles at several medical-device companies, with a focus on commercial-stage surgical technologies. The leadership team has deliberately shifted the firm's identity from a pure surgical-kit vendor toward a platform business, a pivot underscored by the 2021 name change from MRI Interventions to ClearPoint Neuro.

The rebranding signaled a move away from being perceived solely as a maker of disposable surgical devices for MRI suites. By adopting the name of its flagship product platform, management aimed to unify the clinical surgical business with the growing pharma-services and biologics-delivery segment under a single brand identity. The change preceded the divestiture of non-neuro cardiac assets and a strategic reorientation around the brain-intervention platform.